



Development and validation of a nomogram for predicting survival in patients with surgically resected lung invasive mucinous adenocarcinoma

Guochao Zhang^{1#}, Xuefei Wang^{2#}, Jia Jia^{3#}, Zhichao Zuo⁴, Lide Wang¹, Shugeng Gao¹, Liyan Xue³, Qi Xue¹

¹Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; ²Department of Breast Surgery, Chinese Academy of Medical Sciences and Peking Union Medical College, Peking Union Medical College and Hospital, Beijing, China; ³Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; ⁴Department of Radiology, Xiangtan Central Hospital, Xiangtan, China

Contributions: (I) Conception and design: Q Xue, L Xue, G Zhang; (II) Administrative support: Q Xue, S Gao; (III) Provision of study materials or patients: Q Xue, L Xue, G Zhang, J Jia, S Gao; (IV) Collection and assembly of data: G Zhang, X Wang, J Jia, L Wang; (V) Data analysis and interpretation: X Wang, Z Zuo; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

[#]These authors contributed equally to this work.

Correspondence to: Liyan Xue. Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. Email: xuely@cicams.ac.cn; Qi Xue. Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. Email: xueqi@cicams.ac.cn.

Background: Lung invasive mucinous adenocarcinoma (LIMA) is a unique and rare subtype of lung adenocarcinoma. We identified prognostic factors and developed a nomogram for predicting overall survival (OS) in LIMA patients after surgery.

Methods: Patients diagnosed with LIMA between 2008 and 2016 from the Surveillance, Epidemiology, and End Results (SEER) database were randomized into training (n=1,254) and test (n=538) cohorts. A nomogram was established using the prognostic signature from the training cohort after multivariable Cox regression analysis. We externally validated the nomogram in a group of 369 patients from China. We separately tested for accuracy and clinical practicability using Harrell's concordance-index (C-index), calibration plots, and decision curve analysis (DCA).

Results: We included 2,161 patients in the analysis. Seven factors, all of which significantly affected OS, were incorporated into the final model, including age, sex, differentiation grade, the extent of surgery, lymphadenectomy, and T, N, and M stage. C-indexes for the training, test, and external validation cohorts were 0.735, 0.736, and 0.773, respectively. The areas under the time-dependent receiver operating characteristic curves at five years were 0.747, 0.798, and 0.777, respectively. The nomogram was discriminative and well-calibrated when applied to the test and external validation cohorts. Significant between-group differences in OS were observed when classifying groups by nomogram score (log-rank $P < 0.001$). An online web server for clinical use was developed using the nomogram.

Conclusions: The nomogram facilitates accurate prediction of survival for patients with LIMA and can be used to stratify clinical risk groups for individualized treatment.

Keywords: Lung invasive mucinous adenocarcinoma (LIMA); nomogram; overall survival; surgery; Surveillance, Epidemiology, and End Results (SEER)

Submitted Jul 10, 2021. Accepted for publication Nov 04, 2021.

doi: 10.21037/tlcr-21-562

View this article at: <https://dx.doi.org/10.21037/tlcr-21-562>

Introduction

Lung cancer is a prominent global health burden. Lung cancer causes the most cancer-related deaths worldwide (1), and adenocarcinoma is the most common histological type (2,3). Lung invasive mucinous adenocarcinoma (LIMA) is a variant of invasive lung adenocarcinoma, previously referred to as mucinous bronchioloalveolar carcinoma, according to the current 2015 World Health Organization (WHO) lung tumor classes (4).

LIMA consists of goblet and columnar cells with small basal-oriented nuclei, which are associated with abundant intracytoplasmic mucin. LIMAs are uncommon and only account for 2–10% of lung adenocarcinomas (5–8). Their relative rarity is one reason diagnosis of LIMAs is challenging. The non-mucinous lung adenocarcinoma features readily identifiable cell types, whereas the cytologic atypia of LIMA cells is usually inconspicuous. Additionally, LIMA often show lepidic-predominant growth, so it is more difficult to diagnose in the limited biopsy specimens and requires differentiation from metaplasia or bronchiolar adenoma. Moreover, the mixed mucinous adenocarcinoma may be difficult to diagnose from biopsy specimens, which depend on the biopsy site. In contrast, a mucinous adenocarcinoma can be easily identified by the presence of abundant mucin in the surgical specimen (9). However, the clinic-pathological characteristics of patients with LIMA are still unclear, due to the low incidence. Moreover, the prognosis of LIMAs remains controversial. Some studies reported that LIMAs might not be aggressive tumors, and the overall survival (OS) was significantly better than non-mucinous adenocarcinoma (10–12). Other reports showed conflicting results (5,13,14), suggesting that these entities tend to be very heterogeneous. Therefore, understanding the biology of LIMAs and identifying the high-risk factors for survival are crucial.

Nomograms quantify risk by revealing characteristics related to oncologic prognoses (15,16). Until now, no nomograms have been developed to forecast long-term survival outcomes after surgery in LIMAs. Consequently, our goal was to develop a novel nomogram for predicting the survival of surgically resected LIMAs using accepted clinic-pathological variables from the SEER database. A separate cohort was used to validate the nomogram externally.

This article is presented in accordance with the TRIPOD reporting checklist (available at <https://dx.doi.org/10.21037/tlcr-21-562>).

Methods

Study design and patients

We identified patients with LIMAs from 18 cancer registries within the population-based Surveillance, Epidemiology, and End Results (SEER) database [2008–2016] and the SEER*Stat program (version 8.3.5). The SEER database includes about 30% of the population of the United States of America.

In the SEER database, 1,792 patients conformed to the inclusion criteria of our study. All patients were diagnosed with invasive mucinous adenocarcinoma (8,480/3, 8,481/3, or 8,253/3) by histology (ICD-O-3) and underwent surgical resection. We excluded patients younger than 18 years, those with an overall survival of less than one month, and those missing essential information. Patients were randomized into training (n=1,254) and test cohorts (n=538) at a 7:3 ratio. Patients in the training cohort were retrospectively analyzed to construct the nomogram, which was internally validated by the test cohort. We also collected a data set (n=369) from the Cancer Hospital, Chinese Academy of Medical Sciences (CAMS, 2010–2017), to validate the nomogram externally. Inclusion and exclusion criteria were the same as the development cohort. If any information about predictors was missing, patients were excluded from the final risk model.

We collected the following patient-specific information from the databases: clinic-pathological characteristics (sex, age at diagnosis, marital status, primary site, race, tumor size, differentiation grade, tumor node metastasis (TNM) stage, visceral pleural invasion (VPI), and histological subtype); therapy details (extent of surgery, number of lymph nodes dissected, radiotherapy, and chemotherapy); and follow-up records (cause of death, vital survival status, and survival time). Two senior pathologists independently re-evaluated the histologic characteristics of the external validation cohort patients. Given that no well-established histological grading system with clearly defined criteria exists for LIMA, “differentiation grade” was determined according to the new histological grading paradigm for lung adenocarcinoma (8th edition TNM staging); this method is based on architectural predominant subtypes (I) G1 for lepidic adenocarcinoma, (II) G2 for acinar adenocarcinoma and papillary adenocarcinoma, and (III) G3 for micropapillary adenocarcinoma and solid adenocarcinoma.

The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). This study was approved by the Ethics Committee of Cancer Hospital,

Chinese Academy of Medical Sciences and Peking Union Medical College (No. NCC1817) and individual consent for this retrospective analysis was waived.

Outcome

The predicted probability of 1-, 3-, and 5-year OS, based on baseline characteristics, was our primary outcome. OS was defined as the time between LIMA diagnosis and death (or last follow-up for cases where a death was not noted).

Statistical analysis

Nomogram development

We developed the nomogram using age, sex, histology, grade differentiation, primary site, laterality, TNM staging, VPI, radiotherapy, chemotherapy, and surgical extent and lymphadenectomy in the survival analysis. We explored the correlation between those variables and OS using the Kaplan-Meier method and the log-rank test. We developed a Cox proportional hazards model to evaluate independent prognostic factors, and those proposed factors were subsequently incorporated into a nomogram using the “survival” and “RMS” packages. We used the validation cohort to validate the model externally.

Assessing and comparing model performance

We verified the nomogram using calibration and discrimination curves. Calibration refers to the proximity between predicted probabilities and observed outcome frequencies. Discrimination refers to a nomogram's ability to differentiate prognoses in patients with a concordance index (Harrell C-index) as quantization (17). The accuracy of the survival prediction for the maximum and final models were evaluated using time-dependent receiver operating characteristic (ROC) curves and area under the curves (AUCs) at 1, 3, and 5 years.

We performed a decision curve analysis (DCA) to compare the reliability of nomograms, which assessed whether alternative diagnostic or prognostic models were superior to others (18). We compared the nomogram to the traditional TNM staging system by C-index, determining net reclassification improvement (NRI) and integrated discrimination improvement (IDI) (19). The sum-score for each patient was determined using the points for each factor in the nomogram. The optimal cut-off value was determined using the “surv_cutpoint” function of the “survminer” package.

We classified patients into low- and high-risk

groups according to each patient's aggregate score in the nomogram. Based on the multivariable analyses, the selected independent risk factors were subjected to subgroup analysis. The OS for different groups were compared using the Kaplan-Meier method and log-rank test. We also assessed the effects of chemotherapy on OS during the subgroup analysis. An online version of the nomogram can be found at <https://www.shinyapps.io/>, to calculate predicted survival probability over time using survival-related factors.

Two-tailed statistical tests with a significance level set to $P < 0.05$ were employed. The hazard ratio (HR) and 95% confidential interval (CI) for each variable with potential prognostic value was estimated using univariate and multivariate Cox proportional hazard regression models in a forward stepwise manner. Significant variables in univariate analyses ($P < 0.05$) were carried into multivariate analyses. Statistical analyses were conducted with SPSS version 24.0 (IBM Corporation, Chicago, IL, USA) and R version 3.6.3. (<http://www.r-project.org/>).

Results

Participants

We identified 1,792 patients with LIMA from the SEER database, which were assigned randomly to either the training cohort ($n = 1,254$) or the test cohort ($n = 538$). Patient baseline characteristics are shown in *Table 1*. All characteristics among the patients were comparable in the different cohorts. The median patient ages in the training and test cohorts were 67 [interquartile range (IQR), 54–76] and 68.23 (IQR, 54–76) years, respectively. The male to female ratios were 545/709 and 219/319 in the training and validation cohorts, respectively. In the training cohort, 477 (52.6%) were stage I, 325 (35.8%) were stage II, 88 (9.7%) patients were stage III, and 17 (1.9%) patients were stage IV. Systematic mediastinal lymphadenectomy was performed in 1,103 (88.0%) patients, and 289 (23.0%) patients received adjuvant chemotherapy after surgery. In the test cohort, 335 (62.3%), 117 (21.7%), 63 (11.7%), and 23 (4.3%) patients were at stages I, II, III, and IV, respectively. Chemotherapy or radiotherapy was administered in 113 (21.0%) and 36 (6.7%) of patients. The median follow-up period was 44 months [95% confidence interval (CI): 42–46 months] and 42 months (95% CI: 39–46 months) in the training and test cohorts, respectively. The 5-year OS rates in the training and test cohorts were 17.15% and 15.24%.

Table 1 Demographics and clinicopathologic characteristics of the study population

Characteristics	Training cohort (n=1,254), n (%)	Test cohort (n=538), n (%)	External validation cohort (n=369), n (%)
Age (mean ± SD, years)	67.75±10.62	68.23±10.54	57.77±11.04
Sex			
Male	545 (43.5)	219 (40.7)	217 (58.8)
Female	709 (56.5)	319 (59.3)	152 (41.2)
Race			
White	1,058 (84.4)	448 (83.3)	0
Others	196 (15.6)	90 (16.7)	369 (100.0)
Primary site			
Upper lobe	484 (38.6)	198 (36.8)	122 (33.1)
Middle lobe	74 (5.9)	30 (5.6)	19 (5.1)
Lower lobe	683 (54.5)	303 (56.3)	206 (55.8)
Others	13 (1.0)	7 (1.3)	22 (6.0)
Laterality			
Right	705 (56.2)	317 (58.9)	196 (53.1)
Left	549 (43.8)	221 (41.1)	173 (46.9)
VPI			
No/unknown	1,147 (91.5)	485 (90.1)	194 (52.6)
Yes	107 (8.5)	53 (9.9)	175 (47.4)
Differentiation grade			
I	701 (55.9)	283 (52.6)	79 (21.4)
II	463 (36.9)	210 (39.0)	181 (49.1)
III/IV	90 (7.2)	45 (8.4)	109 (29.5)
Histological subtype			
Pure LMIA	1128 (90.0)	488 (90.7)	220 (59.6)
Mixed LMIA	126 (10.0)	50 (9.3)	149 (40.4)
Extent of surgery			
Lobectomy ^a	907 (72.3)	369 (68.6)	315 (85.4)
Sub-lobectomy	296 (23.6)	144 (26.8)	50 (13.6)
Pneumonectomy ^b	51 (4.1)	25 (4.6)	4 (1.1)
Tumor size (mean ± SD, mm)	44.66±98.10	47.63±113.00	33.28±23.12
T stage			
T1	548 (43.7)	251 (46.7)	126 (34.1)
T2	409 (32.6)	164 (30.5)	195 (52.8)
T3	238 (19.0)	100 (18.6)	39 (10.6)
T4	59 (4.7)	23 (4.3)	9 (2.4)

Table 1 (continued)

Table 1 (continued)

Characteristics	Training cohort (n=1,254), n (%)	Test cohort (n=538), n (%)	External validation cohort (n=369), n (%)
N stage			
N0	1,067 (85.1)	515 (95.7)	276 (74.8)
N+	167 (14.9)	23 (4.3)	93 (25.2)
M stage			
M0	1,194 (95.2)	515 (95.7)	361 (97.8)
M1	60 (4.8)	23 (4.3)	8 (2.2)
Number of LND (mean \pm SD)	9.12 \pm 9.98	9.30 \pm 9.63	17.32 \pm 10.61
Adjuvant radiotherapy			
Presence	97 (7.7)	36 (6.7)	21 (5.69)
Absence	1,157 (92.3)	502 (93.3)	348 (94.31)
Adjuvant chemotherapy			
Presence	289 (23.0)	113 (21.0)	126 (34.15)
Absence	965 (77.0)	425 (79.0)	243 (65.85)

^a, including lobectomy and bilobectomy; ^b, including pneumonectomy and lobectomy extended. SD, standard deviation; LIMA, lung mucinous invasive adenocarcinoma; VPI, visceral pleural invasion; LND, lymph nodes dissected.

Univariate and multivariate Cox proportional hazard analyses

Univariate and multivariate Cox regression analyses were employed to detect factors that significantly correlate with OS, as shown in *Table 2*. The univariate analysis revealed that older age ($P<0.0001$), sex ($P<0.0001$), race ($P=0.023$), marital status ($P=0.036$), larger tumor size ($P<0.0001$), primary site ($P=0.004$), poorly differentiated status ($P<0.0001$), more advanced T, N, and M stages (all $P<0.0001$), the extent of surgery ($P<0.0001$), lymphadenectomy ($P<0.0001$), and the absence of radiotherapy or chemotherapy (both $P<0.0001$) significantly correlated with shorter OS. The variables identified in the univariate analyses were employed in the multivariate analysis to determine if they independently associated with OS. Multivariate analyses showed that age ($P<0.0001$), sex ($P=0.001$), differentiation grade ($P<0.0001$), T stage ($P<0.0001$), N stage ($P<0.0001$), M stage ($P=0.001$), the extent of surgery ($P<0.0001$), and lymphadenectomy ($P=0.039$) were able to predict the OS of LIMA patients.

Development of nomogram for OS

A nomogram was constructed for predicting 1-, 3-, and 5-year OS using the independent factors identified in the training cohort, including age, gender, differentiation grade, T, N, and M stage, the extent of surgery, and lymphadenectomy (*Figure 1*). The probability of individual survival was determined by adding up all scores for each factor. The nomogram indicated that the N stage was the most crucial factor affecting the outcome, followed by the T stage, differentiation grade, M stage, the extent of surgery, age, lymphadenectomy, and sex. The C-indices in the training and test cohorts were 0.735 (95% CI: 0.728–0.742) and 0.736 (95% CI: 0.7255–0.7465) for OS. Based on the ROC curve analyses for the 1-, 3-, and 5-year OS, the AUC values were 0.782, 0.756, and 0.747, respectively, in the training cohort (*Figure 2A*) and 0.738, 0.756, and 0.798, respectively, in the test cohort (*Figure 2B*). The C-indices and AUC values indicated that the nomogram possessed accurate predictive and adequate discriminative abilities. Furthermore, we generated calibration plots for probable 1-, 3-, and 5-year OS. All generated plots closely approximated

Table 2 Selected factors for building the model by univariate and multivariate Cox proportional hazards regression analysis in the training cohort

Variable	Univariable analysis			Multivariable analysis		
	HR	95% CI	P value	HR	95% CI	P value
Age (years)						
<60	Reference			Reference		
≥60	1.824	1.361–2.445	<0.0001	1.861	1.375–2.519	<0.0001
Sex						
Female	Reference			Reference		
Male	1.543	1.261–1.888	<0.0001	1.432	1.158–1.773	0.001
Race						
White	Reference			Reference		
Others	0.692	0.504–0.950	0.023	0.787	0.571–1.086	0.145
Marital status						
Married	Reference			Reference		
Others	1.251	1.015–1.541	0.036	1.064	0.857–1.320	0.574
Tumor size (mm)						
<50	Reference			Reference		
≥50	1.527	1.210–1.929	<0.0001	1.137	0.856–1.510	0.376
Primary site			0.004			0.062
Lower lobe	Reference			Reference		
Middle lobe	0.983	0.627–1.542	0.942	0.943	0.594–1.496	0.803
Upper lobe	1.090	0.881–1.347	0.427	0.977	0.783–1.220	0.840
Others	3.422	1.754–6.676	<0.0001	2.515	1.264–5.005	0.009
Laterality						
Right	Reference					
Left	1.184	0.967–1.449	0.102			
Histological subtype						
Pure LMIA	Reference					
Mixed LMIA	1.208	0.892–1.635	0.222			
VPI						
No/unknown	Reference					
Yes	1.211	0.859–1.708	0.274			
Differentiation grade			<0.0001			<0.0001
I	Reference			Reference		
II	1.940	1.566–2.404	<0.0001	1.665	1.326–2.091	<0.0001
III/IV	2.889	2.054–4.064	<0.0001	1.947	1.339–2.832	<0.0001

Table 2 (continued)

Table 2 (continued)

Variable	Univariable analysis			Multivariable analysis		
	HR	95% CI	P value	HR	95% CI	P value
Extent of surgery			<0.0001			<0.0001
Sub-lobectomy	Reference			Reference		
Lobectomy ^a	0.551	0.443–0.686	<0.0001	0.579	0.434–0.773	<0.0001
Pneumonectomy ^b	0.709	0.426–1.178	0.184	0.453	0.259–0.791	0.005
Lymphadenectomy						
No	Reference			Reference		
Yes	0.518	0.399–0.674	<0.0001	0.701	0.501–0.982	0.039
T stage			<0.0001			<0.0001
T1	Reference			Reference		
T2	1.595	1.239–2.053	<0.0001	1.549	1.182–2.029	0.002
T3	2.204	1.681–2.890	<0.0001	2.153	1.544–3.004	<0.0001
T4	6.148	4.279–8.834	<0.0001	2.167	1.358–3.458	0.001
N stage						
N0	Reference			Reference		
N+	2.091	1.843–2.372	<0.0001	1.645	1.379–1.961	<0.0001
M stage						
M0	Reference			Reference		
M1	3.557	2.571–4.922	<0.0001	1.975	1.343–2.906	0.001
Radiotherapy						
Presence	Reference			Reference		
Absence	2.750	2.078–3.639	<0.0001	1.281	0.925–1.775	0.136
Chemotherapy						
Presence	Reference			Reference		
Absence	2.122	1.718–2.622	<0.0001	0.889	0.673–1.173	0.405

^a, including lobectomy and bilobectomy; ^b, including pneumonectomy and lobectomy extended. HR, hazard ratio; CI, confidence interval; MIA, mucinous invasive adenocarcinoma; VPI, visceral pleural invasion.

the observed estimates in the training and test cohorts (Figure 3A,3B), demonstrating that the two groups were well-calibrated. The newly developed nomogram reliably predicted survival in patients with LIMA after surgical resection.

Validation of the nomogram

The external validation cohort included 369 patients in the final analysis. Table 1 shows the baseline characteristics of

the external cohort. Solitary-type was found in 348 (94.31%) patients, while pneumonic-type was found in 21 (5.69%) patients. The follow-up time was 53.6 months (median, 95% CI: 50.2–58.0 months) and the 5-year OS rate was 34.69%. The nomogram C-index for predicting OS was 0.773 (95% CI: 0.760–0.786). AUC values for the 1-, 3-, and 5-year OS were 0.826, 0.800, and 0.777, respectively (Figure 3C). Moreover, the external calibration plots for predicted probabilities of 1-, 3-, and 5-year OS also showed adequate consistency (Figure 3D).




Figure 1 Prognostic nomogram of 1-, 3- and 5-year OS for surgically resected LIMA patients. ^a, including pneumonectomy and lobectomy extended; ^b, including lobectomy and bilobectomy.




Figure 2 Time-dependent receiver operating characteristic (ROC) curves and the area under the curves (AUCs) at 1-, 3- and 5-year in the training cohort (A) and the test cohort (B) were used to estimate the prognostic accuracy of the nomogram.

The prognostic nomogram in the clinical practice

An exploratory examination of the nomogram predictive value for risk stratification was conducted. A total risk score was determined for each patient in the training cohort. Based on these calculations, the cut-off value of the sum-score was 263. We then grouped the training cohort into high-risk (scores >263) or low-risk (scores ≤263) groups (Figure S1). The low-risk patients had significantly longer OS compared with high-risk patients (log-rank, $P < 0.001$) (Figure 4A). The same cut-off value for OS also differentiated high- and low-risk groups in the test cohort (log-rank, $P < 0.001$) and external validation cohort (log-rank, $P < 0.001$) (Figure 4B, 4C). Similarly, the high-risk group had a significantly shorter OS than the low-risk group in the three integrated cohorts (log-rank, $P < 0.001$) (Figure 4D).

To further verify the nomogram's stability in different clinical subgroups, we conducted a stratified analysis in patients with pure LIMA and mixed LIMA to evaluate the nomogram's predictive ability. The nomogram could accurately classify OS for patients in high- and low-risk groups (log-rank, all $P < 0.001$) (Figure S2).

Comparison of predictive accuracy for OS in the current nomogram versus the conventional AJCC staging systems

The clinical validity of the nomogram was verified using a DCA, demonstrating the superior benefits of the new model compared with the 7th edition TNM staging system. The nomogram was better than the conventional AJCC staging system at predicting survival in LIMA patients (Figure 5A-5C). The C-index for OS of our nomogram was significant




Figure 3 The calibration curves for predicting the 1-, 3- and 5-year OS of patients in the training cohort (A), the test cohort (B). The X-axis indicates the predicted survival probability, and the Y-axis indicates the actual survival probability. The 45-degree line (gray line) indicates that the prediction agrees with actuality. Time-dependent receiver operating characteristic (ROC) curves and the area under the curves (AUCs) at 1-, 3- and 5-year in the external validation cohort (C). The calibration curves for predicting the 1-, 3- and 5-year OS of patients in the external validation cohort (D).

higher than that of the conventional TNM staging system in the training cohort (0.735 *vs.* 0.694, respectively), in the test cohort (0.736 *vs.* 0.712, respectively), and the external validation cohort (0.773 *vs.* 0.741, respectively). Notably, the NRI values were 0.233 (95% CI: 0.128 to 0.384), 0.084 (95% CI: -0.015 to 0.288), and 0.245 (95% CI: -0.106 to 0.409) in the training, test, and external validation cohorts, respectively. The IDI values were 0.245 (95% CI: -0.106 to 0.409), 0.038 (95% CI: 0.014–0.087), and 0.032 (95% CI: 0.010–0.113) in the training, test, and external validation cohorts, respectively. Thus, our nomogram predicted prognosis better than conventional TNM staging.

Development of a web server for accessing the new model

An online version of the nomogram is located at <https://doctor1.shinyapps.io/DynNomap/> (Figure S3) and may help guide risk-reducing interventions and survival predictions for clinicians. Predicted survival can be determined by inputting clinical features into the web server.

Discussion

LIMA is a distinct pulmonary malignancy, whose biological behaviors and clinicopathological features remain unclear. Several previous studies reported that the clinicopathological characteristics and prognosis of LIMA are unique from other subtypes of lung adenocarcinoma (20–23). However, survival data for LIMA in the few published reports tend to be contradictory. These differences suggested that the prognosis of LIMA patients is heterogeneous. Given that the previous LIMA studies were limited to small sample sizes, clarification of the prognostic factors based on a large cohort and development of a model to predict LIMA patient overall survival is urgently needed.

In the present study, we enrolled 2,161 patients with LIMA, a much bigger cohort than previous LIMA studies. From the SEER database, 1,792 patients with LIMA were identified, which were split randomly into training ($n=1,254$) and test cohorts ($n=538$). We used univariate and multivariate Cox proportional hazard




Figure 4 Kaplan-Meier curves of OS for risk stratification in the training cohort (A), the test cohort (B), the external validation cohort (C), and the three integrated cohorts (D).




Figure 5 DCA of nomogram prediction model and TNM staging system for 5-year OS in the training cohort (A), the test cohort (B), and the external validation cohort (C). The red dotted line represents the DCA of nomogram, in contrast, the green dotted line represents the DCA of the traditional TNM staging system. DCA, decision curve analysis.

analyses to analyze independent prognostic factors based on clinicopathological characteristics in the training cohort. We then identified seven independent prognostic factors, including age, sex, differentiation grade, the extent of surgery, lymphadenectomy, and T, N, and M stages, which were incorporated into the nomogram. The nomogram was successfully validated using an external cohort of 369 patients with LIMA. Encouragingly, the proposed nomogram revealed excellent discrimination and calibration. This is the first nomogram able to predict OS in patients with surgically-resected LIMA, based on the SEER database and an external validation cohort. More importantly, the number of patients included in most previous studies was relatively small. In contrast, at present, our study is the largest cohort of LIMA patients with long-term follow-up.

We identified differentiation grade, extent of surgery, and lymphadenectomy as independent predictors for overall survival, in addition to the risk factors of age, sex, and T, N, and M stages. Previous studies indicated that several of these variables were risk factors related to survival in patients with LIMA (10,24). In this study, female patients have a better survival than male patients, which may be related to the more populations of stage I in female patients. Moreover, female patients are more likely to be younger, never-smokers, and demonstrate EGFR-driver mutations and the p53 wild-type transcription factor—all of which are protective factors in lung cancer (25,26). Of note, surgical methods and regional lymph node examination are independent prognostic factors for LIMAs, as demonstrated by this study. Surgical resection is the primary treatment for operable LIMAs, and most guidelines indicate that lobectomy is the most common surgery for patients with lung adenocarcinoma. Interestingly, we found that patients who underwent pneumonectomy or lobectomy had a better prognosis than those who underwent sub-lobectomy. In the prognostic nomogram, the risk score of pneumonectomy was less than lobectomy (0 *vs.* 23 points); however, there was no significant difference between pneumonectomy and lobectomy ($P=0.322$). Although resection of more tissue may improve survival for patients with pneumonic-type LIMA, lobectomy is still gold-standard surgical procedure for LIMA. Furthermore, patients who had a lymphadenectomy had a more favorable survival than those who did not. These results are consistent with Moon *et al.* (11), suggesting that patients undergoing lymphadenectomy with adequate pathologic staging had improved survival.

Our univariate analysis results indicate that adjuvant

chemotherapy and radiotherapy are significantly related to prolonged OS. However, these same parameters were negatively associated with OS in the multivariate analysis. This may be attributed to interactions between chemotherapy and age and TNM stage. Luo *et al.* found no significant survival benefits from adjuvant chemotherapy for postoperative patients with LIMA (8). Cha *et al.* reported that in stage IV LIMA patients, treatment with chemotherapy did not improve OS (12). Moreover, LIMA patients possessed a distinct molecular signature and lack of targetable mutations (20,22,27,28). Thus, this population might not benefit from targeted therapy with tyrosine kinase receptor inhibitors, and a new therapeutic approach is urgently warranted.

In the present study, 3.33% of lung cancer patients in the SEER database had LIMA and 2.13% of lung cancer patients in the Cancer Hospital, Chinese Academy of Medical Sciences had LIMA. The most common primary site of LIMA was the lower lobe. LIMA patients tended to be less advanced in the SEER database and validation cohort, consistent with previous results (10-12). Given that there were some differences between pure LIMA and mixed LIMA, we conducted a subgroup analysis of OS. This analysis demonstrated that the high-risk group had a significantly shorter OS compared with the low-risk group in both the pure and mixed LIMA subgroups. Of note, we used the nomogram to stratify patients with LIMA into prognostic risk groups. There is an urgent need to identify appropriate candidates for postoperative adjuvant therapy.

The risk factors incorporated into the survival prediction model were readily ascertainable clinicopathological variables. Their inclusion minimizes patient data collection variability and improves the general applicability of this model, making it an easy-to-use scoring system. A few nomograms have been developed to predict the prognosis of patients with mucinous adenocarcinoma. Chen *et al.* developed a prognostic nomogram for LIMA with a C-index of 0.724 (10). However, all LIMA patients were enrolled, including the advanced stage patients diagnosed with a transbronchial biopsy. We focused only on LIMA patients who underwent surgery because diagnosis of LIMA based on surgical specimens can be easily identified while its definitive diagnosis by transbronchial biopsy before surgery is more challenging.

The American Joint Committee on Cancer TNM classification is the most extensively utilized staging system (29); however, patient survival at the same stage varies widely (30-32). Other independent prognostic factors,

including sex, age, histology, and treatment-related factors, may contribute significantly to predicting individualized survival. Therefore, we aimed to develop a model to better stratify LIMAs into different prognostic categories. Our study revealed that the C-index for 1-/3-/5-year OS in the nomogram was higher compared with the traditional TNM staging system and previously published model. The nomogram displayed adequate calibration plots for the 1-/3-/5-year OS scores in the training, test, and external validation cohorts. DCA is a novel method for assessing diagnostic tests and predictive models. In this study, the clinical utility was in the proper range. Additionally, the ideal net benefits (the C-index, NRI and IDI values) of the new model were superior to the 7th edition TNM staging system, suggesting that this model may be a practical instrument to provide personalized predictions for patients with LIMA.

Although the nomogram proved to be an effective independent prognostic determiner for patients with LIMA, there are several limitations. First, this was a retrospective study, incurring inevitable bias. Further prospective studies may be required to validate the risk model. Second, the nomogram did not include some crucial predictors, such as a history of smoking, lymphovascular invasion, chemotherapy regimens, and the predominant growth pattern of LIMAs, due to the non-availability of this information in the SEER database. Third, potential interaction terms were not considered in this nomogram for improving its convenience and interpretability. Consideration of all reasonable interaction terms in the model construction may result in a better survival prediction; however, it would make the model more complex and difficult to use for clinical practice. Last but not least, the lung cancer TNM staging system applied in our study was the 7th edition, because the current 8th edition stage information was not available in the SEER database. Although there are some discrepancies between different editions of staging systems, the prognostic values are consistent and they are constantly being optimized. Despite these limitations, our prognostic nomogram, combined with the online web server, is an essential and useful model, which provides accurate and individualized survival predictions in LIMA patients.

Conclusions

We developed and validated the first nomogram for patients with surgically resected LIMA based on the SEER database and a large external cohort. This nomogram can improve

prognostic assessment, aid individual treatment, and guide follow-up management strategies for patients with LIMA.

Acknowledgments

All authors would like to thank all patients and staff who have participated in and contributed to the SEER program tumor registries. We also would like to thank Karen Uray and Erin P. Silverman for their help in polishing our paper.

Funding: This work was supported by funds from the National Key Research and Development Program of China (2018YFC1311601, 2016YFC1303200).

Footnote

Reporting Checklist: The authors have completed the TRIPOD reporting checklist. Available at <https://dx.doi.org/10.21037/tlcr-21-562>

Data Sharing Statement: Available at <https://dx.doi.org/10.21037/tlcr-21-562>

Peer Review File: Available at <https://dx.doi.org/10.21037/tlcr-21-562>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://dx.doi.org/10.21037/tlcr-21-562>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). This study was approved by the Ethics Committee of Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (No. NCC1817) and individual consent for this retrospective analysis was waived.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the

formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018;68:394-424.
- Gridelli C, Rossi A, Carbone DP, et al. Non-small-cell lung cancer. *Nat Rev Dis Primers* 2015;1:15009.
- Duma N, Santana-Davila R, Molina JR. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. *Mayo Clin Proc* 2019;94:1623-40.
- Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. *J Thorac Oncol* 2015;10:1243-60.
- Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. *Mod Pathol* 2011;24:653-64.
- Sun F, Wang P, Zheng Y, et al. Diagnosis, clinicopathological characteristics and prognosis of pulmonary mucinous adenocarcinoma. *Oncol Lett* 2018;15:489-94.
- Cai D, Li H, Wang R, et al. Comparison of clinical features, molecular alterations, and prognosis in morphological subgroups of lung invasive mucinous adenocarcinoma. *Onco Targets Ther* 2014;7:2127-32.
- Luo J, Wang R, Han B, et al. Analysis of the clinicopathologic characteristics and prognostic of stage I invasive mucinous adenocarcinoma. *J Cancer Res Clin Oncol* 2016;142:1837-45.
- Cha YJ, Shim HS. Biology of invasive mucinous adenocarcinoma of the lung. *Transl Lung Cancer Res* 2017;6:508-12.
- Chen Z, Li M, Ma K, et al. Analysis of the clinicopathological characteristics, genetic phenotypes, and prognostic of pure mucinous adenocarcinoma. *Cancer Med* 2020;9:517-29.
- Moon SW, Choi SY, Moon MH. Effect of invasive mucinous adenocarcinoma on lung cancer-specific survival after surgical resection: a population-based study. *J Thorac Dis* 2018;10:3595-608.
- Cha YJ, Kim HR, Lee HJ, et al. Clinical course of stage IV invasive mucinous adenocarcinoma of the lung. *Lung Cancer* 2016;102:82-8.
- Casali C, Rossi G, Marchioni A, et al. A single institution-based retrospective study of surgically treated bronchioloalveolar adenocarcinoma of the lung: clinicopathologic analysis, molecular features, and possible pitfalls in routine practice. *J Thorac Oncol* 2010;5:830-6.
- Yanagawa N, Shiono S, Abiko M, et al. New IASLC/ATS/ERS classification and invasive tumor size are predictive of disease recurrence in stage I lung adenocarcinoma. *J Thorac Oncol* 2013;8:612-8.
- Iasonos A, Schrag D, Raj GV, et al. How to build and interpret a nomogram for cancer prognosis. *J Clin Oncol* 2008;26:1364-70.
- Liang W, Zhang L, Jiang G, et al. Development and validation of a nomogram for predicting survival in patients with resected non-small-cell lung cancer. *J Clin Oncol* 2015;33:861-9.
- Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. *Stat Med* 1996;15:361-87.
- Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. *Med Decis Making* 2006;26:565-74.
- Van Calster B, Van Huffel S. Integrated discrimination improvement and probability-sensitive AUC variants. *Stat Med* 2010;29:318-9.
- Nakagomi T, Goto T, Hirotsu Y, et al. Genomic Characteristics of Invasive Mucinous Adenocarcinomas of the Lung and Potential Therapeutic Targets of B7-H3. *Cancers (Basel)* 2018;10:478.
- Lee HY, Cha MJ, Lee KS, et al. Prognosis in Resected Invasive Mucinous Adenocarcinomas of the Lung: Related Factors and Comparison with Resected Nonmucinous Adenocarcinomas. *J Thorac Oncol* 2016;11:1064-73.
- Shim HS, Kenudson M, Zheng Z, et al. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung. *J Thorac Oncol* 2015;10:1156-62.
- Ritterhouse LL, Vivero M, Mino-Kenudson M, et al. GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas. *Mod Pathol* 2017;30:1720-7.
- Geles A, Gruber-Moesenbacher U, Quehenberger F, et al. Pulmonary mucinous adenocarcinomas: architectural patterns in correlation with genetic changes, prognosis and survival. *Virchows Arch* 2015;467:675-86.
- Chapman AM, Sun KY, Ruestow P, et al. Lung cancer

- mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers. *Lung Cancer* 2016;102:122-34.
26. Haupt S, Caramia F, Herschtal A, et al. Identification of cancer sex-disparity in the functional integrity of p53 and its X chromosome network. *Nat Commun* 2019;10:5385.
 27. Righi L, Vatrano S, Di Nicolantonio F, et al. Retrospective Multicenter Study Investigating the Role of Targeted Next-Generation Sequencing of Selected Cancer Genes in Mucinous Adenocarcinoma of the Lung. *J Thorac Oncol* 2016;11:504-15.
 28. Hwang DH, Sholl LM, Rojas-Rudilla V, et al. KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung. *J Thorac Oncol* 2016;11:496-503.
 29. Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. *J Thorac Oncol* 2016;11:39-51.
 30. Zeng Y, Mayne N, Yang CJ, et al. A Nomogram for Predicting Cancer-Specific Survival of TNM 8th Edition Stage I Non-small-cell Lung Cancer. *Ann Surg Oncol* 2019;26:2053-62.
 31. Shang X, Yu H, Lin J, et al. A Novel Nomogram including AJCC Stages Could Better Predict Survival for NSCLC Patients Who Underwent Surgery: A Large Population-Based Study. *J Oncol* 2020;2020:7863984.
 32. Sculier JP, Chansky K, Crowley JJ, et al. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. *J Thorac Oncol* 2008;3:457-66.

Cite this article as: Zhang G, Wang X, Jia J, Zuo Z, Wang L, Gao S, Xue L, Xue Q. Development and validation of a nomogram for predicting survival in patients with surgically resected lung invasive mucinous adenocarcinoma. *Transl Lung Cancer Res* 2021;10(12):4445-4458. doi: 10.21037/tlcr-21-562




Figure S1 The optimal cut-off value as determined by sum-score was 263.




Figure S2 Kaplan-Meier curves of OS for risk stratified by histological subtypes in a subgroup analysis. Kaplan-Meier curves of OS for risk stratification in patients with pure LIMA in the SEER cohort (A); Kaplan-Meier curves of OS for risk stratification in patients with mixed LIMA in the SEER cohort (B); Kaplan-Meier curves of OS for risk stratification in patients with pure LIMA in the external validation cohort (C), Kaplan-Meier curves of OS for risk stratification in patients with mixed LIMA in the external validation cohort (D).

LIMA

Age
 >60 years old

Sex
 Male

Differentiatin.grade
 Poorly differentiated

Lymphadenectomy
 No

Extent.of.surgery
 Sub-bobectomy

T.stage
 T4

N.stage
 N+

M.stage
 M1

☒ Predicted Survival at this Follow Up:

time
 1 60 83

☒ Alpha blending (transparency)




Figure S3 Online web server interface for the dynamic prognostic nomogram of LIMA patients.